Glentac 150 Tablet contains Ranitidine 150 mg, a histamine H2-receptor antagonist used primarily to reduce gastric acid secretion. It is indicated for the treatment and prevention of conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and erosive esophagitis. Ranitidine works by selectively inhibiting H2 receptors on gastric parietal cells, thereby decreasing the volume and concentration of gastric acid produced. This reduction in acid helps alleviate symptoms like heartburn, acid indigestion, and sour stomach, while promoting healing of ulcers and inflammation in the gastrointestinal tract. Glentac 150 is typically administered orally, with dosage and duration tailored according to the specific condition and patient response. It is generally well-tolerated, though potential side effects may include headache, dizziness, constipation, or diarrhea. Caution is advised in patients with renal or hepatic impairment, and it should be used under medical supervision to avoid masking symptoms of more serious conditions such as gastric malignancy. Glentac 150 should not be used concomitantly with certain drugs without professional consultation due to possible interactions. Overall, Glentac 150 offers effective acid suppression for managing acid-related gastrointestinal disorders.